BreakBio’s patent-pending treatment is designed to make personalized vaccines that target several types of cancers, starting with metastatic colorectal cancer

Colorectal cancer is the second most deadly cancer, after lung cancer.

Existing treatments for this cancer are not effective.

Given that patients who have had poor results from chemotherapy, have no meaningful treatment options today, the FDA could award Breakthrough Therapy Designation. This is awarded if early clinical data shows “substantial improvement over existing therapy”. Achieving this breakthrough is our key goal.


BreakBio’s patent-pending Personalized Cancer Control (PCC) 

Cancer Vaccine Tailor Made for Each patient.
Treatment is in two parts


Proprietary AI Vaccine Design Model

Analyzes the cancer cells in each patient
Then BreakBio manufactures a unique vaccine per patient

Proven colorectal cancer (CRC) drugs

Reduces barriers to immune system and
Slows rate of growth of cancer cells

Two arms: One combination for patients who have not progressed on chemo
Different combination for patients who have progressed on chemo

Get in touch

Looking for information or if you have questions, we are here to help.